<code id='6455E75DBD'></code><style id='6455E75DBD'></style>
    • <acronym id='6455E75DBD'></acronym>
      <center id='6455E75DBD'><center id='6455E75DBD'><tfoot id='6455E75DBD'></tfoot></center><abbr id='6455E75DBD'><dir id='6455E75DBD'><tfoot id='6455E75DBD'></tfoot><noframes id='6455E75DBD'>

    • <optgroup id='6455E75DBD'><strike id='6455E75DBD'><sup id='6455E75DBD'></sup></strike><code id='6455E75DBD'></code></optgroup>
        1. <b id='6455E75DBD'><label id='6455E75DBD'><select id='6455E75DBD'><dt id='6455E75DBD'><span id='6455E75DBD'></span></dt></select></label></b><u id='6455E75DBD'></u>
          <i id='6455E75DBD'><strike id='6455E75DBD'><tt id='6455E75DBD'><pre id='6455E75DBD'></pre></tt></strike></i>

          hotspot

          hotspot

          author:entertainment    Page View:62945
          Jeremey Wyatt ActiGraph

          As drugmakers wade into using digital health technologies, ActiGraph has made its mission to become the wearable of choice for the industry.

          The Pensacola, Fla.-based company creates  devices and software explicitly designed for clinical trials by focusing on features that matter to sponsors, like bulletproof reliability, access to raw sensor data, and 30-day battery life so that trial participants never have to worry about charging devices.

          advertisement

          There are many potential advantages to using wearables in clinical trials. Continuous data may collect a more comprehensive picture of how a patient responds to treatment and could help drugmakers complete trials faster with fewer participants. But risk-averse companies have been slow to adopt the technology and opt instead for the certainty of established methods for capturing data. The industry has yet to see a drug approved with evidence from a wearable device.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          explore

          How one medical school became remarkably diverse
          How one medical school became remarkably diverse

          ThefirstclassattheUniversityofCalifornia,Davismedicalschool,in1972,waspredominantlywhiteandmale.Chri

          read more
          Feng Zhang suggests Editas didn’t move quickly enough to find product targets
          Feng Zhang suggests Editas didn’t move quickly enough to find product targets

          ScientistFengZhang,right,isinterviewedbyreporterMeganMolteniatSTAT'sBreakthroughSummitEast.STATWhent

          read more
          Duchenne breakthrough therapy leaves behind pioneering families
          Duchenne breakthrough therapy leaves behind pioneering families

          DuchennemusculardystrophyDr.EdwinP.Ewing,Jr./CDCPatFurlongwassittinginherhomeofficeinMiddletown,Ohio

          read more

          Syphilis numbers in the United States reach record heights

          Atissuesamplewiththepresenceofnumerous,corkscrew-shaped,darklystainedTreponemapallidumspirochetes,th